Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Observer Bermuda.
Press releases published on September 3, 2025
WeightWatchers Advances International Growth With Strategic Leadership Appointment
GlobeNewswire
·
September 3, 2025
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced the appointment of Alejandro Bethlen as Executive Vice President, …
WeightWatchers treibt internationales Wachstum mit strategischer Verstärkung im Führungsteam voran
GlobeNewswire
·
September 3, 2025
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) („WeightWatchers“ oder das „Unternehmen“), der weltweit führende, wissenschaftlich fundierte Experte für Gewichtsmanagement i, gab heute bekannt, dass Alejandro Bethlen mit …
Fangzhou Secures 2nd National Science Foundation Project Approval, Deepens AI-Driven Healthcare Research
GlobeNewswire
·
September 3, 2025
SHANGHAI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its technology team will collaborate on a National Natural Science Foundation of China …
Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor
GlobeNewswire
·
September 3, 2025
Lehi, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, September 3, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that Gordon Ringold, PhD has …
Renovamen Advisors® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models
GlobeNewswire
·
September 3, 2025
Renovamen Advisors® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models Guiding biotech teams from scientific breakthroughs to commercial inflection with investor-grade strategy and execution Chicago, IL …
Allegro appoints life sciences veteran as Chief Operating Officer to advance osteoarthritis treatment
GlobeNewswire
·
September 3, 2025
Stephan Crokaert, formerly of NeoMedLight, Abbott, Adagio and Boston Scientific, brings more than 35 years of strategic and commercial experience in life sciences Allegro prepares to advance lead product hydrocelin into clinical trials in 2026 Liege, …
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
GlobeNewswire
·
September 3, 2025
Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypes No safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with …
Valneva annonce de nouvelles données positives d’innocuité et d’immunogénicité de Phase 2 pour le candidat vaccin contre la maladie de Lyme
GlobeNewswire
·
September 3, 2025
Forte réponse immunitaire chez les enfants et les adultes après la troisième vaccination annuelle de rappel Forte réponse anamnestique observée pour les six sérotypes Aucun problème de sécurité observé dans toutes les tranches d’âge par le comité …
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer
GlobeNewswire
·
September 3, 2025
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer Seasoned clinical development leader brings deep expertise in neuromuscular disease research, drug development, and commercialization in the US and …
BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected
GlobeNewswire
·
September 3, 2025
LOS ANGELES and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today provided an update regarding …
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
GlobeNewswire
·
September 3, 2025
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), …